Biohaven Ltd. (BHVN)
| Previous Close | 38.72 |
| Open | 38.95 |
| Bid | 37.99 x 1300 |
| Ask | 38.42 x 1000 |
| Day's Range | 36.77 - 38.44 |
| 52 Week Range | 12.35 - 62.21 |
| Volume | |
| Avg. Volume | 1,295,082 |
| Market Cap | 3.321B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.73 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 59.63 |
GuruFocus.comDirector Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd (BHVN)
On April 24, 2024, Gregory Bailey, Director of Biohaven Ltd (NYSE:BHVN), purchased 25,503 shares of the company, as reported in a recent SEC Filing.
GuruFocus.comDirector Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd (BHVN)
Director Gregory Bailey has recently increased his stake in Biohaven Ltd (NYSE:BHVN) by purchasing 48,780 shares of the company's stock, according to a SEC Filing dated 2024-04-22.
PR NewswireBiohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the closing of its underwritten public offering of 6,451,220 of its common shares, which includes the full exercise of the underwriters' option to purchase 841,463 additional common shares, at a public offering price of $41.00 per share. The gross proceeds from t
